IP Library Patent Application 12773000
Patent Application
App. No. 12/773,000

FORMULATIONS OF LIQUID STABLE ANTITHROMBIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/773,000
Abstract

In one aspect, the invention provides liquid stable formulations of antithrombin.

Claims (16)

1 . A formulation comprising: antithrombin, a buffer, a carboxylic acid, a disaccharide sugar and a salt.

2 . The formulation of claim 1 , wherein the formulation does not include a surfactant.

3 . The formulation of claim 1 , wherein the antithrombin is recombinant human antithrombin (rhAT).

4 . The formulation of claim 1 , wherein the antithrombin has a concentration of 45 to 55 mg/ml.

5 . The formulation of claim 1 , wherein the carboxylic acid is sodium citrate.

6 . The formulation of claim 1 , wherein the carboxylic acid has a concentration of 50 to 600 mM.

7 . The formulation of claim 1 , wherein the buffer is a tris-phosphate buffer.

8 . The formulation of claim 1 , wherein the buffer is between 1 mM and 100 mM.

9 . The formulation of claim 1 , wherein the pH is between 7.5 and 8.5.

10 . The formulation of claim 1 , wherein the disaccharide sugar is sucrose.

11 . The formulation of claim 1 , wherein the disaccharide sugar is 0.5 to 5% of volume by weight.

12 . The formulation of claim 1 , wherein the salt is sodium chloride.

13 . The formulation of claim 1 , wherein the salt has a concentration of between 25 mM and 100 mM.

14 . The formulation of claim 1 , wherein the antithrombin has a concentration of 50 mg/ml, wherein the carboxylic acid is sodium citrate and has a concentration of 300 mM, wherein the disaccharide sugar is sucrose and is 1% of volume by weight, wherein the salt is sodium chloride and has a concentration of 50 mM.

15 . The formulation of claim 14 , wherein the antithrombin is antithrombin alfa.

16 . The formulation of claim 14 , wherein the buffer is 10 mM tris-phosphate and the pH is 8.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2014
From: REVO BIOLOGICS, INC.
To: LFB USA, INC.
Reel/Frame 032846/0172 →
CHANGE OF NAME Recorded Jul 18, 2013
From: GTC BIOTHERAPEUTICS, INC.
To: REVO BIOLOGICS, INC.
Reel/Frame 030831/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2010
From: MAGNESON, GERALD R.; ALLARD, GREG J.; MASIELLO, NICHOLAS C.; PATEL, USHA S.; FONTANA, LAUREN K.; PEARCE, JOSEPH L.; GRANDONI, JERRY A.
To: GTC BIOTHERAPEUTICS, INC.
Reel/Frame 025532/0344 →